Ann: Change of Director's Interest Notice - Michael Perry, page-16

I continue to follow these threads on AVH--not because they are informative ,more so entertaining.

I fully endorse Gaucau's views on the potential. I have no doubt this Company will succeed and be acquired once the alternative product applications (vitilago, DVU/DFU, cosmetics)are proven and rolled out.
In the interim it will be a slow build in value as the Burns application and adoption grows not only in the US markets but Japan/Europe. Recell is truly a disruptive biotech.

However I too remain frustrated and annoyed at the approach adopted by Perry.

He has a quality CV and track record it appears however; he came in late to the CEO role (FDA was all but done prior to his appointment) and he has been over compensated with incentive shares.
As noted; there appears to be a pattern of positive market updates, an allotment of incentives and yes, the sell down for "tax purposes".
I don't recall ever seeing a CEO sell on EVERY allotment of incentives. We are overcompensating him and we are effectively paying his tax for him......Not happy.